AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 141 min read$AZN

AstraZeneca PLC (AZN) Shares Surge 4.0% -- What GF Score of 76 T

AstraZeneca PLC (AZN) shares rose 4.0% to $162.03 on October 14, 2026. The stock is trading 10.7% below its fair value estimate of $181.41, according to GF Value™. AZN's GF Score™ is 76/100, indicating strong profitability and growth, but weak momentum. Insiders have net sold $2.2M in the past year. The P/E ratio is 24.2x, below its 5-year median of 33.2x.

Original reporting
gurufocus.com
Published Oct 14, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 10:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$AZN
Neutral
medium confidence
Mentioned
$AZN
Relevance
4/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$AZNNeutralLow
01

Why it matters

The article highlights a modest price increase and valuation gap but offers no fresh catalyst.

02

Market read

A short‑term price move with limited trading relevance; valuation discussion is largely reiterative.

03

What to watch

Potential upcoming earnings or pipeline news could change the valuation narrative.

Relevance 4/10Novelty 2/10Timing: today

Background

GuruFocus provides valuation and GF Score analysis for listed companies.

Company-level read

Ticker impact

$AZNNeutralMedium confidence
Context

Shares rose 4.0% to $162.03, with GF analysis showing the stock is 10.7% below its fair value estimate.

Expected impact

potential pressure as market prices in low momentum and insider selling

Evidence & confidence

The article provides valuation metrics but no new catalyst; the recent rise is likely short‑term and may face downside.

Market effects

Sector

Limited impact on the broader pharma sector; valuation discussion is company‑specific.

Regional

Primarily UK‑listed; minimal immediate effect on US markets.

Global

Low

Counterpoint

What could challenge this read

Despite the 4% rise, the low momentum score and insider selling suggest the stock may underperform.

Key entities

  • company
    AstraZeneca PLC

    UK‑based pharmaceutical company, ticker AZN.

Read at source← All news

Related articles

OCT 15
$AZNMed

AstraZeneca And insitro Enter AI Drug Discovery Collaboration Worth Up To Approximately $1.5 Billion

AstraZeneca and insitro have partnered to use AI for drug discovery, focusing on metabolic dysfunction-associated steatohepatitis and cardiomyopathies. insitro will receive $40 million upfront and up to $1.46 billion in milestones. AstraZeneca gains exclusive rights to advance selected programs. The collaboration aims to accelerate drug development using insitro's AI platform and AstraZeneca's clinical expertise.

pulse2.com3 min
OCT 15
$AZNMed

AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion

AstraZeneca and insitro have agreed to collaborate on drug discovery using AI to target metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. Insitro will receive $40 million upfront and up to $1.46 billion in milestones. AstraZeneca will lead development and commercialization, with exclusive worldwide rights to the programs. The collaboration aims to leverage insitro's AI platform for identifying disease drivers and novel targets.

pharmexec.com6 min
OCT 15
$AZNMed

Insitro, AstraZeneca Sign AI Drug Discovery Deal

Insitro and AstraZeneca (AZN) have partnered to use AI for drug discovery in MASH and cardiomyopathies. Insitro receives $40M upfront, with up to $1.46B in milestones and royalties. AZN stock rose 3.99% Wednesday, and is up 2.82% in pre-market trading.

rttnews.com1 min